Want to see HCAT full AI Analyst Report?
HCAT Stock Chart & Stats
$1.59
$0.07(3.48%)
At close: 4:00 PM EDT
$1.59
$0.07(3.48%)
Day’s Range― - ―
52-Week Range$0.96 - $3.62
Previous Close$2.08
Volume423.78K
Average Volume (3M)784.36K
Market Cap
$130.19M
Enterprise Value$213.72
Total Cash (Recent Filing)$103.44M
Total Debt (Recent Filing)$169.98M
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Nov 10, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.68
Shares Outstanding75,256,380
10 Day Avg. Volume377,240
30 Day Avg. Volume784,360
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.68
Price to Sales (P/S)0.54
P/FCF Ratio-704.86
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$1.83Price Target Upside14.78% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)-0.05
Revenue Forecast (FY)$247.73M
Bulls Say, Bears Say
Bulls Say
Debt Elimination And Balance-sheet StrengthDebt elimination materially improves financial flexibility by removing approximately $16.5M of annual cash interest and reducing refinancing exposure. The remaining cash balance gives Health Catalyst greater capacity to fund product investment, manage its transition, and withstand operating volatility.
Positive Free Cash Flow GenerationThe turnaround to positive operating and free cash flow is an important source of internal funding, particularly after debt repayment. If maintained, stronger cash conversion can support technology investment and reduce reliance on external capital despite continued reported accounting losses.
Recurring Healthcare Analytics Business ModelSubscription-based software revenue can create recurring customer relationships and opportunities to expand usage across applications, data domains, users, and capabilities. That model provides a foundation for durable revenue visibility and operating leverage as deployments mature and adoption broadens.
Bears Say
Persistent Large LossesVery large ongoing losses show that gross profit is not yet covering the company’s cost structure and other charges. Until profitability improves, Health Catalyst has less resilience to execution setbacks, and the durability of its recent cash generation remains uncertain.
Declining Revenue TrendA declining top line weakens the foundation for scale benefits and makes it harder to absorb fixed technology and operating costs. Revenue contraction also limits confidence that product adoption is currently offsetting portfolio changes and customer migration effects.
Migration-related Churn And Margin PressureMigration disruption creates a material risk to recurring revenue and customer retention while imposing duplicate hosting, data-loading, and deployment costs before revenue recognition. These pressures can persist across several quarters and delay margin expansion during the transition.
Health Catalyst News
HCAT FAQ
What was Health Catalyst’s price range in the past 12 months?
Health Catalyst lowest stock price was $0.95 and its highest was $3.62 in the past 12 months.
What is Health Catalyst’s market cap?
Health Catalyst’s market cap is $130.19M.
When is Health Catalyst’s upcoming earnings report date?
Health Catalyst’s upcoming earnings report date is Nov 10, 2026 which is in 59 days.
How were Health Catalyst’s earnings last quarter?
Health Catalyst released its earnings results on Aug 06, 2026. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.01.
Is Health Catalyst overvalued?
According to Wall Street analysts Health Catalyst’s price is currently Undervalued.
Does Health Catalyst pay dividends?
Health Catalyst does not currently pay dividends.
What is Health Catalyst’s EPS estimate?
Health Catalyst’s EPS estimate is -0.05.
How many shares outstanding does Health Catalyst have?
Health Catalyst has 75,256,380 shares outstanding.
What happened to Health Catalyst’s price movement after its last earnings report?
Health Catalyst reported an EPS of $0.04 in its last earnings report, beating expectations of $0.03. Following the earnings report the stock price went down -25.108%.
Which hedge fund is a major shareholder of Health Catalyst?
Currently, no hedge funds are holding shares in HCAT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Health Catalyst Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.83 (14.78% Upside)
$1.83 (14.78% Upside)
Blogger Sentiment
Neutral
HCAT Sentiment 100%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Decreased
By 300.5K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.53%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-41.80%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Health Catalyst
Health Catalyst, Inc. equips healthcare providers with crucial data and analytical technologies, alongside specialized services. Their extensive product line features a robust, enterprise-level data and analytics platform designed specifically for the healthcare sector. They additionally offer advanced artificial intelligence (AI) and data science solutions that integrate AI seamlessly into existing business intelligence tools, thereby enhancing analytical precision. The company's services also cover population health management, which identifies areas for improvement throughout the patient care journey, offering actionable recommendations and automated processes. For financial effectiveness, they provide critical insights into cost analysis, workforce efficiency, and revenue maximization. Moreover, Health Catalyst contributes to improving quality and safety by leveraging clinical and patient safety data, sophisticated analytics, and expert consulting. They also facilitate a national data ecosystem, promoting collaborative thought leadership and shared knowledge to generate groundbreaking insights that redefine healthcare delivery. Established in 2008 and based in South Jordan, Utah, the company was formerly known as HQC Holdings, Inc. before officially becoming Health Catalyst, Inc. in March 2017.
HCAT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call communicated meaningful strategic progress: a completed divestiture that eliminated debt and interest costs, cost reductions via Project Nexus, a Q2 revenue beat and adjusted EBITDA at the high end of guidance, and continued investments in technology and AI. However, the near-term picture is constrained by the loss of Vitalware's revenue/EBITDA contribution, persistent migration-related churn and at-risk ARR, margin pressure from dual operating costs during migrations, and a lowered full-year revenue/EBITDA outlook. Management frames these as deliberate, multiyear transformation actions that improve the capital structure and position the company for long-term growth while acknowledging short-term revenue and margin headwinds.View all HCAT earnings summariesHCAT Stock 12 Month Forecast
Average Price Target
$1.83
▲(14.78% Upside)
Technical Analysis
Evolent Health
―
Phreesia
―
Privia Health Group
―
Definitive Healthcare Corp
―
Waystar Holding Corp.
―
Ownership Overview
7.13% Insiders
13.05% Mutual Funds
45.69% Other Institutional Investors
28.20% Public Companies and
Individual Investors